AC T04213
XX
ID T04213
XX
DT 23.01.2001 (created); dkl.
DT 18.11.2014 (updated); asv.
CO Copyright (C), QIAGEN.
XX
FA Smad5
XX
SY Smad-5.
XX
OS mouse, Mus musculus
OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae
XX
GE G002405 Smad5.
XX
CL C0041; SMAD; 7.1.1.1.4.
XX
SF the aa sequence shown here retrieved from EMBL #AF063006 differs in aa 196 from the other EMBL entry MMU77638 (S/P);
SF localized on chromosome 13 between the markers Hivep1 and Cspg2 and a high linkage was determined for marker 119 [1];
SF +/- mutants appear phenotypically normal [3];
SF -/- mutant embryos died at E10.5-E11.5 of gestation, primarily due to yolk sac defects [3];
XX
CP (embryo): E7, E8.5 in mesenchyme, E10.5 in somites and mesenchyme and endothelium, E11.5, E15.5, E17.5 [3]; (adult): heart, brain, spleen, lung, liver, skeletal muscle, kidney, testis [1] [3] [1] [3].
XX
FF Loss of SMAD-5 blocks angiogenesis, leading to death of -/- embryos [3];
FF -/- mutant embryos: at E8-E8.25 no obvious difference between mutants and littermates, at E8.5 -/- mutant embryos are smaller and some showed delayed fusion between allantois and chorion [3];
FF at 9.5 mutant embryos are retarded in development and many exhibited a lateral spreading of the ventral mesoderm [3];
FF -/- mutant embryos exhibited malformation of blood vessels [3];
FF reduced mesenchyme in -/- embryos is accompanied by massive apoptosis [3];
XX
IN T04864 SIP1; mouse, Mus musculus.
XX
MX M03846 V$SMAD5_Q5.
MX M08829 V$SMAD5_Q5_01.
MX M08897 V$SMAD_Q4.
MX M00974 V$SMAD_Q6_01.
XX
BS R19605.
BS R64103.
BS R64104.
BS R71669.
BS R32807.
BS R32808.
BS R63126.
BS R63127.
BS R33295.
BS R38502.
BS R63147.
BS R63149.
BS R63150.
XX
DR TRANSPATH: MO000020386.
DR UniProtKB: P97454; P70341.
XX
RN [1]; RE0015120.
RX PUBMED: 9076683.
RA Meersseman G., Verschueren K., Nelles L., Blumenstock C., Kraft H., Wuytens G., Remacle J., Kozak C.A., Tylzanowski P., Niehrs C., Huylebroeck D.
RT The C-terminal domain of Mad-like signal transducers is sufficient for biological activity in the Xenopus embryo and transcriptional activation
RL Mech. Dev. 61:127-140 (1997).
RN [2]; RE0015603.
RA Chang H., Kraft H., Verschueren K., Wang P., Huylebroeck D., Matzuk M. M.
RT Genomic organization and expression of mouse Smad5
RL direct submission (EMBL) : ().
RN [3]; RE0015671.
RX PUBMED: 10079220.
RA Yang X., Castilla L. H., Xu X., Li C., Gotay J., Weinstein M., Liu P. P., Deng C.-X.
RT Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5
RL Development 126:1571-1580 (1999).
RN [4]; RE0018465.
RX PUBMED: 10504300.
RA Ebisawa T., Tada K., Kitajima I., Tojo K., Sampath T. K., Kawabata M., Miyazono K., Imamura T.
RT Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation
RL J. Cell Sci. 112:3519-3527 (1999).
RN [5]; RE0020663.
RX PUBMED: 10224135.
RA Ishisaki A., Yamato K., Hashimoto S., Nakao A., Tamaki K., Nonaka K., ten Dijke P., Sugino H., Nishihara T.
RT Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells
RL J. Biol. Chem. 274:13637-13642 (1999).
RN [6]; RE0054287.
RX PUBMED: 18039466.
RA Kochupurakkal B. S., Sarig R., Fuchs O., Piestun D., Rechavi G., Givol D.
RT Nanog inhibits the switch of myogenic cells towards the osteogenic lineage.
RL Biochem. Biophys. Res. Commun. 365:846-850 (2008).
RN [7]; RE0022866.
RX PUBMED: 11927558.
RA Goumans M. J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P.
RT Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.
RL EMBO J. 21:1743-1753 (2002).
XX
//